the meaning set forth in Exhibit B. 1.39 "Effective Date" has the meaning set forth in the preamble to this Agreement. 1.40 "Expiration Date" means March 31, 2020. 1.41 "FDA" means the United States Food and Drug Administration or any successor agency thereto. 1.42 "Fee Notice" has the meaning set forth in Section 5.5.1. 1.43 "First Position Detail" means, with respect to any product, a detail or presentation that is dedicated solely to such product and constitutes at least 70% of the total presentation time for all products presented during a Call in which such product is the first product presented to the health care professional. 1.44 "Force Majeure" has the meaning set forth in Section 14.2. 1.45 "GAAP" means United States generally accepted accounting principles applied on a consistent basis. Unless otherwise defined or stated, financial terms shall be calculated by the accrual method under GAAP. 1.46 "Governmental Authority" means any government (including any national, federal, state or local government), or political subdivision thereof, or any multinational or other organization, authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal, or any governmental arbitrator or arbitral body (or any department, bureau or division of any of the foregoing). 1.47 "Health Care Professional" means a health care professional with prescribing authority who treats urothelial cancer. 1.48 "Indemnified Party" has the meaning set forth in Section 12.2.1. 1.49 "Indemnifying Party" has the meaning set forth in Section 12.2.1. 1.50 "Initial Indication" means the first indication for which the Product receives Marketing Approval in the Territory, which the Parties expect to be treatment of adult patients with locally advanced or metastatic urothelial carcinoma which has (a) susceptible FGFR 3 or 2 genetic alterations and (b) progressed during or following